Healthcare -
Medical - Devices - NYSE - US
$ 131.98
0.887 %
$ 229 B
Market Cap
17.27
P/E
1. INTRINSIC VALUE
Balance Sheet
Abbott Laboratories
| Current Assets | 23.7 B |
| Cash & Short-Term Investments | 7.97 B |
| Receivables | 9.5 B |
| Other Current Assets | 6.19 B |
| Non-Current Assets | 57.8 B |
| Long-Term Investments | 886 M |
| PP&E | 10.7 B |
| Other Non-Current Assets | 46.2 B |
| Current Liabilities | 14.2 B |
| Accounts Payable | 4.2 B |
| Short-Term Debt | 1.5 B |
| Other Current Liabilities | 8.46 B |
| Non-Current Liabilities | 19.4 B |
| Long-Term Debt | 13.5 B |
| Other Non-Current Liabilities | 5.84 B |
EFFICIENCY
Earnings Waterfall
Abbott Laboratories
| Revenue | 42 B |
| Cost Of Revenue | 18.7 B |
| Gross Profit | 23.2 B |
| Operating Expenses | 16.4 B |
| Operating Income | 6.82 B |
| Other Expenses | -6.58 B |
| Net Income | 13.4 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Abbott Laboratories
| Net Income | 13.4 B |
| Depreciation & Amortization | 3.22 B |
| Capital Expenditures | -2.21 B |
| Stock-Based Compensation | 673 M |
| Change in Working Capital | -9.22 B |
| Others | -8.34 B |
| Free Cash Flow | 6.35 B |
Wall Street Analysts Price Targets
Abbott Laboratories
Wall Street analysts predict an average 1-year price target for ABT of $135 , with forecasts ranging from
a
low of
$50 to a high of $345 .
ABT Lowest Price Target
Wall Street Target
50 USD
-62.12%
ABT Average Price Target
Wall Street Target
135 USD
2.32%
ABT Highest Price Target
Wall Street Target
345 USD
161.40%
4. DIVIDEND
ANALYSIS
0.49%
DIVIDEND YIELD
0.59 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Abbott Laboratories
Sold
0-3 MONTHS
77.9 M USD 9
3-6 MONTHS
18.4 M USD 1
6-9 MONTHS
16.5 M USD 2
9-12 MONTHS
3.48 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
2025 Dividend Kings: Strong Run Continues
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings identified in February showed relative outperformance, averaging -0.38% vs. -1.58% for all Kings and -3.34% for SPY.
seekingalpha.com
- 2 weeks ago
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
zacks.com
- 2 weeks ago
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock?
ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.
zacks.com
- 2 weeks ago
Abbott Stock Could Be On The Verge Of A Breakout - Here's What Smart Money Sees
Abbott Laboratories is undervalued by the market, despite its strong fundamentals and strategic moves in high-growth areas like diabetes care and weight-loss treatments. The company boasts a high net income margin of 31.95% and generates over $8.5 billion in cash from operations, providing significant flexibility. Abbott's FreeStyle Libre system and new Protality brand highlight its long-term growth potential in diabetes care and weight-loss treatment markets.
seekingalpha.com
- 2 weeks ago
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
zacks.com
- 3 weeks ago
2 Dependable Dividend Stocks That Can Pay You for Life
What makes an outstanding dividend stock? High yields can seem attractive to income seekers, but unless a company has a steady, reliable business, payout cuts are a real possibility no matter how juicy its dividend yield.
fool.com
- 4 weeks ago
Strong Earnings Lift Abbott Laboratories Shares
Health care company Abbott Laboratories (ABT) increases sales, earnings around the globe.
fxempire.com
- 4 weeks ago
The Dividend Aristocrats Ranked By Quality Scores: March 2025
S&P Dow Jones Indices added three new members to the S&P 500 Dividend Aristocrats Index, expanding it to 69 companies. I rank Dividend Aristocrats by quality scores, presenting undervalued and overvalued stocks with detailed metrics and fair value estimates. My quality scoring system uses six indicators, each worth 5 points, for a maximum score of 30, categorizing stocks from Exceptional to Inferior.
seekingalpha.com
- 1 month ago
Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion
WAYNE, Penn.--(BUSINESS WIRE)-- #CLI--Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent.
businesswire.com
- 1 month ago
AHCO vs. ABT: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with AdaptHealth Corp. (AHCO) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?
zacks.com
- 1 month ago
My Best Dividend Aristocrats For March 2025
The ProShares S&P 500 Dividend Aristocrat ETF kicks off 2025 on a bright note with a gain of 2.81% in January. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 43 months of tracking these strategies, one strategy is generating a CAGR superior to NOBL.
seekingalpha.com
- 1 month ago
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
zacks.com
- 1 month ago
8. Profile
Summary
Abbott Laboratories ABT
COUNTRY
US
INDUSTRY
Medical - Devices
MARKET CAP
$ 229 B
Dividend Yield
0.49%
Description
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Contact
100 Abbott Park Road, North Chicago, IL, 60064-6400
https://www.abbott.com
IPO
Date
March 17, 1980
Employees
114000
Officers
Mr. Robert B. Ford
Chairman of the Board, President & Chief Executive Officer
Mr. Philip P. Boudreau
Chief Financial Officer & Executive Vice President of Finance
Mr. Hubert L. Allen J.D.
Executive Vice President, General Counsel & Secretary
Ms. Lisa D. Earnhardt
Executive Vice President & Group President of Medical Devices
Ms. Melissa Brotz
Senior Vice President of Global Marketing & External Affairs
Ms. Sabina Ewing
Senior Vice President of Business & Technology Services and Chief Information Officer
Ms. Mary K. Moreland
Executive Vice President of Human Resources
Mr. Michael Comilla
Vice President of Investor Relations.
Erica L. Battaglia
Vice President and Chief Ethics & Compliance Officer
Mr. Daniel Gesua Sive Salvadori
Executive Vice President and Group President of Established Pharmaceuticals & Nutritional Products